A Critical Review of the Evidence for a Continuous Hemostasis in vivo

I. Conclusions

Injury to vessels leads to the formation of platelet plugs and fibrin clots. For nearly a century it has been known that these mechanisms stop bleeding and may produce thrombi. They may be triggered by trivial trauma (180), and hemostasis possibly occurs in one or more vessels at all times in the normal body. The blood is capable of removing at least the fibrin part of such deposits; however, some of them may progress into arteriosclerotic lesions (59). The accumulated evidence, therefore, supports the concept of a hemostatic balance on the local level, triggered by an abnormal local factor.

In this review, however, we are concerned with a general and continuous hemostasis which takes place on the normal, uninjured endothelium. Direct examinations have suggested that hemostatic products are present on normal endothelium, but these investigations cannot be accepted as conclusive. Much of the indirect evidence is weak or controversial. However, the purpura and increased capillary fragility in platelet disorders strongly suggest that platelets are important for vascular integrity, and animal experiments suggest that both platelets and coagulation influence vascular permeability. At present, therefore, the theory of continuous hemostasis can neither be accepted nor rejected; further evidence must be collected.

^* John S. McEachern Fellow from the Canadian Cancer Society 1959—1960.

• References

• (1) Aas K. Prokonvertin og konvertin. 90 Thesis Akad. Trykningssentral; Oslo: 1952
• (2) Aas K. Personal communication. 1961
• (3) Aas K, Gardner F. H. Survival of blood platelets labeled with chromium⁵¹ . J. clin. Invest. 37: 1257 1958;
• (4) Ackroyd J. F. The pathogenesis of thrombocytopenic purpura due to hypersensitivity to sedormid. Clin. Sci. 7: 249 1949;
• (5) Ackroyd J. F. The function of factor VII. Brit. J. Haemat. 2: 397 1956;
• (6) Adelson E, Rheingold J. J, Parker O. Platelet and fibrinogen sequestration. Blood 15: 596 1960;
• (7) Adelson E, Rheingold J. J, Parker O, Buenaventura A, Crosby W. H. Platelet and fibrinogen survival in normal and abnormal states of coagulation. Blood 17: 267 1961;
• (8) Adelson E, Rheingold J. J, Parker O, Steiner M, Kirby J. C. Survival of plasma thromboplastin component and antihemophilic globulin in normal humans. Clin. Res. 8: 369 1960;
• (9) Aggeler P. M. Physiological basis for transfusion therapy in hemorrhagic disorders: a critical review. Transfusion 1: 71 1961;
• (10) Aggeler P. M, Fowell A. H, Johnson F. F, Hoag S, Pool J. G. Intravenous use of a concentrated plasma P. T. C. preparation. Proc. VI. Int. Congr. Hernat. 490 Boston 1956 Grune & Stratton; New York: 1958
• (11) Alexander B. Coagulation, hemorrhage and thrombosis. New Eng. J. Med. 252: 432 484, 526 1955;
• (12) Alkjaersig N, Seegers W. H. Formation of prothrombin from autoprothrombin by means of liver mitochondria. Amer. J. Physiol. 183: 111 1955;
• (13) Allen E. V. The clinical use of anticoagulants. J. Amer. med. Ass. 134: 323 1947;
• (14) Allen J. G. Homeostatic hemostasis. Arch. Surg. 63: 279 1951;
• (15) Allen J. G, Moulder P. V, Emerson D. M, Basinger C, Landy J. J, Glotzer D. J. The physiology of intravascular coagulation in health and disease. Surg. Clin. N. Amer. 37: 1473 1957;
• (16) Ambrus J. L, Ambrus C. M, Sokal J. E, Markus G, Back N, Stutzman L, Razis D, Ross C. A, Smith B. H, Rekate A. C, Collins G. L, Kline D. L, Fishman J. B. Clinical pharmacology of various types of fibrinolytic enzyme preparations. Amer. J. Cardiol. 6: 462 1960;
• (17) Andrus W, Lord Jr J. W, Kauer J. T. Studies on the fate of plasma prothrombin. Science 91: 48 1940;
• (18) Astrup T. Fibrinolysis in the organism. Blood 11: 781 1956;
• (19) Astrup T. The haemostatic balance. Thromb. Diath haem. 2: 347 1958;
• (20) Astrup T. Role of blood coagulation and fibrinolysis in the pathogenesis of arteriosclerosis. 223 in Connective tissue, thrombosis, and atherosclerosis. Edit, by Page I. H. 316 Acad. Press; New York: 1959
• (21) Barnhart M. I. Generation of prothrombin activity with mitochondria or with cathepsin. Amer. J. Physiol. 189: 527 1957;
• (22) Beaumont J. L, Bernard J. Syndrome hémorragique congenital dû au défaut du facteur de coagulation, récemment isolé sous le nom de Facteur VII, Convertine, S. P. C. A. Acta med. Scand. 145: 200 1953;
• (23) Bedson S. P. Blood-platelet anti-serum, its specificity and rôle in the experimental production of purpura. Part. II. J. Path. Bact. 25: 94 1922;
• (24) Bergsagel D. E, Hougie C. Intermediate stages in the formation of blood thromboplastin. Brit. J. Haemat. 2: 113 1956;
• (25) Bidwell E. Fibrinolysins of human plasma. Biochem. J. 55: 497 1953;
• (26) Bigelow R. R, Furth J, Woods M. C, Storey R. H. Endothelial damage by X-rays disclosed by lymph fistula studies. Proc. Soc. exp. Biol. (N. Y.) 76: 734 1951;
• (27) Biggs R. Assay of antihaemophilic globulin in treatment of haemophilic patients. Lancet 2: 311 1957;
• (28) Biggs R, Douglas A. S. The measurement of prothrombin in plasma. A case of prothrombin deficiency. J. clin. Path. 6: 15 1953;
• (29) Biggs R, Macfarlane R. G, Pilling J. Observations on fibrinolysis. Experimental activity produced by exercise or adrenaline. Lancet 1: 402 1947;
• (30) Billimoria J. D, Drysdale J, James D. C. O, Maclagan N. F. Determination of fibrinolytic activity of whole blood. Lancet 2: 471 1959;
• (31) Bizzozero J. Über einen neuen Formbestandteil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung. Virchows Arch. path. Anat. 90: 261 1882;
• (32) Bollman J. L, Preston F. W. The effects of experimental administration of dicoumarin. 3,31-methylene-bis-(4-hydroxycoumarin). J. Amer. med. Ass. 120: 1021 1942;
• (33) Bolton F. G, Clarke J. E. A method of assaying Christmas factor; its application to the study of Christmas disease (Factor-IX deficiency). Brit. J. Haemat. 5: 396 1959;
• (34) Borchgrevink C. F. Platelet adhesion in vivo in patients with bleeding disorders. Acta med. scand.. In press 1961
• (35) Borchgrevink C. F, Egeberg O, Pool J. G, Skulason T, Stormorken H, Waaler B. A study of a case of congenital hypoprothrombinaemia. Brit. J. Haemat. 5: 294 1959;
• (36) Bounameaux Y. Dosage des facteurs de coagulation contenus dans l’athmosphère plasmatique des plaquettes humaines. Rev. franç. Ét. clin. biol. 2: 52 1957;
• (37) Brambel C. E. The role of flavonoids in coumarin anticoagulant therapy. Ann. N. Y. Acad. Sci. 61: 678 1955;
• (38) Brinkhous K. M. Blood clotting: the plasma procoagulants. Ann. Rev. Physiol. 21: 271 1959;
• (39) Buckell M, Elliott F. A. Diurnal fluctuation of plasma-fibrinolytic activation in normal males. Lancet 1: 660 1959;
• (40) Caglio M. Contribution à l’étude du métabolisme de la prothrombine. V. int. Congr. Hernat.. Paris: 1954: 181 in program.
• (41) van Cauwenberge H, Jaques L. B. Prothrombin time and hemorrhagic death in dicumarolized rats receiving pituitary and adrenal hormones. Thromb. Diath. haem. 3: 45 1959;
• (42) Chambers R, Zweifach B. W. Intercellular cement and capillary permeability. Physiol. Rev. 27: 436 1947;
• (43) Clark W. G. Effect of Rutin on dicoumarolization. Proc. Soc. exp. Biol. (N. Y.) 69: 97 1948;
• (44) Cliffton E. E. Physiological mechanisms of fibrinolysis. Acta haemat. (Basel) 20: 76 1958;
• (45) Copley A. L. Effet capillorragique de la fibrinolysine et de l’antifibrinolysine sur la membrane nictitante du lapin normal et exposé aux rayons X. Arch. int. Pharmacodyn. 99: 426 1954;
• (46) Copley A. L. Thrombosis and thrombo-embolization in blood capillaries. Proc. I. int. Conf. Thrombosis and Embolism in Basel 1954. 452 Schwabe; Basel: 1955
• (47) Cronkite E. P. Regulation of platelet production. Brookhaven Symposia in Biology 10: 96 1957;
• (48) Cronkite E. P, Bond V. P, Robertson J. S, Paglia D. E. The survival, distribution and apparent interaction with capillary endothelium of transfused radiosulfate labeled platelets in the rat. J. clin. Invest. 36: 881 1957;
• (49) Cronkite E. P, Jackson D. P. Use of platelet transfusions in hemorrhagic disease. Progress in Hematology. Edit, by Tocantins L. M. 2 239 Grune and Stratton; New York: 1959
• (50) Dam H. The antihaemorrhagic vitamin of the chick. Occurrence and chemical nature. Nature 135: 652 1935;
• (51) Dameshek W, Rubio Jr F, Mahoney J. P, Reeves W. H, Bürgin L. A. Treatment of idiopathic thrombocytopenic purpura (ITP) with prednisone. J. Amer. med. Ass. 166: 1805 1958;
• (52) Danielli J. F. Capillary permeability and oedema in the perfused frog. J. Physiol. 98: 109 1940;
• (53) Desai R. G, Fulton G. P. Evidence for a vessel wall defect in immuno-thromboytopenic hamsters. Blood 15: 675 1960;
• (54) Deutsch E. Die Hemmkörperhämophilie. 112 Sormeen; Wien: 1950
• (55) Deutsch E. Die hämophilie-ähnlichen hämorrhagischen Diathesen. Ergehn. inn. Med. Kinderheilk. 5: 553 1954;
• (56) Deutsch E, Fischer M. Die Wirkung intravenös applizierter Streptokinase auf Fibrinolyse und Blutgerinnung. Thromb. Diath. haem. 4: 482 1960;
• (57) Dormont J, Alagilleet D, Soulier J. P. Les avitaminoses K aiguës idiopathiques. Leur traitement par la vitamine K. Path. Biol. 7: 1881 1959;
• (58) Duckert F. On the properties of the Stuart-Prower factor. Thromb. Diath. haem. Suppl. 4: 32 1960;
• (59) Duguid J. B. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J. Path. Bact. 58: 207 1946;
• (60) Egeberg O. Acquired circulating anticoagulant in classical hemophilia. Scand. J. clin. Lab. Invest.. In print. 1961
• (60a) Egeberg O. Assay of antihemophilic A, B and C factors by one-stage cephalin systems. Scand. J. clin. Lab. Invest. 13: 140 1961;
• (61) Elliott Jr R. H. E, Whipple M. A. Observations on the interrelationship of capillary, platelet, and splenic factors in thrombocytopenic purpura. J. Lab. clin. Med. 26: 489 1940; 1941
• (62) Faloon W. W, Greene R. W, Lozner E. L. The hemostatic defect in thrombocytopenia as studied by the use of ACTH and cortisone. Amer. J. Med. 13: 12 1952;
• (63) Fanti P, Nelson J. F. Coagulation in lymph. J. Physiol. 122: 33 1953;
• (64) Fanti P, Sawers R. F, Man A. G. Investigation of a haemorrhagic disease due to beta-prothromboplastin deficiency complicated by a specific inhibitor of thromboplastin formation. Aust. Ann. Med. 5: 163 1956;
• (65) Favre-Gilly J, Thouverez J. P. Les inhibiteurs de la première phase de la coagulation en dehors de l’hémophilie. Sang 30: 351 1960;
• (66) Fearnley G. R. Spontaneous fibrinolysis. Amer. J. Cardiol. 6: 371 1960;
• (67) Fearnley G. R, Balmforth G, Fearnley E. Evidence of a diurnal fibrinolytic rhythm; with a simple method of measuring natural fibrinolysis. Clin. Sci. 16: 645 1957;
• (68) Fearnley G. R, Lackner R. The fibrinolytic activity of normal blood. Brit. J. Haemat. 1: 189 1955;
• (69) Fearnley G. R, Tweed J. M. Evidence of an active fibrinolytic enzyme in the plasma of normal people with observations on inhibition associated with the presence of calcium. Clin. Sci. 12: 81 1953;
• (70) Fletcher A. P, Alkjaersig N, Sherry S. The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J. clin. Invest. 38: 1096 1959;
• (71) Friedman M, Rosenman R. H, Carroll V. Changes in the serum cholesterol and blood clotting time in men subjected to cyclic variation of occupational stress. Circulation 17: 852 1958;
• (72) Fulton G. P, Akers R. P, Lutz B. R. White thrombo-embolism and vascular fragility in the hamster cheek pouch after anticoagulants. Blood 8: 140 1953;
• (73) Gitlin D. Immunochemistry and its relationship to atherosclerosis. 285 in Connective Tissue, Thrombosis, and Atherosclerosis. Edit, by Page I. H. 316 Acad. Press; New York: 1959
• (74) Gitlin D, Borges W. H. Studies on the metabolism of fibrinogen in two patients with congenital afibrinogenemia. Blood 8: 679 1953;
• (75) Godai H. C, Hasselback R, Hjort P. F. The recovery of thrombin from plasma. Scand. J. clin. Lab. Invest.. In press.
• (76) Goldstein R, Alexander B, Zonderman E. B. The role of proconvertin in citrate or thromboplastin conversion of prothrombin. Proc. VI. int. Congr. Hernat., Boston 1956. 598 Grune & Stratton; New York: 1958
• (77) Goldstein R, Le Bolloc’h A, Alexander B, Zonderman E. Preparation and properties of prothrombin. J. biol. Chem. 234: 2857 1959;
• (78) Graham J. B. Stuart clotting defect and Stuart factor. Thromb. Diath. haem. Suppl. 4: 22 1960;
• (79) Gross R, Gerok W, Löhr G. W, Vogell W, Waller H. D, Theopold W. Über die Natur der Thrombasthénie. Klin. Wschr. 1960: 193.
• (80) Gross R, Illig L, Macher E. Kombinierte Untersuchungen hämorrhagischer Diathesen. Thromb. Diath. haem. 1: 55 223 1957;
• (81) Grossman C. M, MacEwan A. M, Dilley J. The half-life of human platelet phosphatide. Nature 188: 950 1960;
• (82) Hagen P. S, Watson C. J. Idiopathic (familial) hypoprotrombinemia. J. Lab. clin. Med. 33: 542 1948;
• (83) Hammond J. D. S, Verel D. Observations on the distribution and biological half-life of human fibrinogen. Brit. J. Haemat. 5: 431 1959;
• (84) Hartenbach W. Die Einwirkung von Dicumarol auf die Leberfunktion und auf das Kapillarsystem. Dtsch. med. Wschr. 1951: 340.
• (85) Hasselback R, Hjort P. F. Effect of heparin on in vivo turnover of clotting factors. J. appl. Physiol. 15: 945 1960;
• (86) Hellem A. J. The adhesiveness of human blood platelets in vitro. Scand. J. clin. Lab. Invest. (Suppl. 51) 12: 117 1960;
• (87) Hellem A, Borchgrevink C. F, Ames S. B. The role of red cells in haemostasis: the relation between haematocrit, bleeding time, and platelet adhesiveness. Brit. J. Haemat. 7: 42 1961;
• (88) Hirsch E. O, Gardner F. H. The transfusion of human blood platelets. J. Lab. clin. Med. 39: 556 1952;
• (89) Hjort P. F. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand. J. clin. Lab. Invest. (Suppl. 27) 9: 183 1957;
• (90) Hjort P. F, Borchgrevink C. F, Iversen O. H, Stormorken H. The effect of heparin on the bleeding time. Thromb. Diath. haem. 4: 389 1960;
• (91) Hjort P. F, Egeberg O. Turnover of prothrombin, Factor VII and factor IX in a patient with hemophilia A. Scand. J. clin. Lab. Invest.. In print.
• (92) Hjort P. F, Perman V, Cronkite E. P. Fresh, disintegrated platelets in radiation thrombocytopenia: correction of prothrombin consumption without correction of bleeding. Proc. Soc. exp. Biol. (N. Y.) 102: 31 1959;
• (93) Hjort P, Rapaport S. I, Owren P. A. Evidence that platelet accelerator (platelet factor I) is adsorbed plasma proaccelerin. Blood 10: 1139 1955;
• (94) Hjort P, Rapaport S. I, Owren P. A. A simple, specific one-stage prothrombin assay using Russell’s viper venom in cephalin suspension. J. Lab. clin. Med. 46: 89 1955;
• (95) Hitzig W. H, Zollinger W. Kongenitaler Faktor-VII-Mangel. Familienuntersuchung und physiologische Studien über den Faktor VII. Helv. paediat. Acta 13: 189 1958;
• (96) Hoag M. S, Aggeler P. M, Fowell A. H. Disappearance rate of concentrated proconvertin extracts in congenital and acquired hypoproconvertinemia. J. clin. Invest. 39: 554 1960;
• (97) Hooff A. van den. Electron-microscopy of atheroma. Lancet 2: 1392 1955;
• (98) Hooff A. van den. Electron-microscopy of atheroma. Lancet 1: 247 1956;
• (99) Hougie C. Circulating anticoagulants. Brit. med. Bull. 11: 16 1955;
• (100) Howell W. H. The coagulation of lymph. Amer. J. Physiol. 35: 483 1914;
• (101) Hugues J. Contribution a l’étude des facteurs vasculaires et sanguins dans l’hémostase spontanée. Thesis. 151 Vaillant-Carmanne; Liege: 1953
• (102) Humble J. G. The mechanism of petechial hemorrhage formation. Blood 4: 69 1949;
• (103) Iversen T, Bastrup-Madsen P. Congenital familial deficiency of factor V (parahaemophilia) combined with deficiency of antihaemophilic globulin. Brit. T. Haemat. 2: 265 1956;
• (104) Jaques L. B, Mogenson G. J, Fisher L. M. The relation of stress to hemorrhage and prothrombin time following anticoagulants. Trans. roy. Soc. Can., Sect. V. 50: 9 1956;
• (105) Jensen H. Dynamic concept of fibrin formation and lysis in relation to hemorrhage (capillary permeability) and to thrombosis. Exp. Med. Surg. 14: 189 1956;
• (106) Jensen H, Gray E, Schaefer Jr E. H. Studies on the mechanism of blood clotting. Proc. I. int. Conf. Thrombosis and Embolism in Basel 1954. 46 Schwabe; Basel: 1955
• (107) Johow R. Die Bekämpfung der Kapillarschäden und der dadurch bedingten Blutungen bei der Behandlung der Thrombose mit Dicumarinen. Med. Klin. 1949: 1288.
• (108) Jubelirer R. A, Glueck H. I. Capillary fragility studies (Göthlin test) on one hundred patients receiving dicumarol. J. Lab. clin. Med. 34: 448 1949;
• (109) Jürgens R. Experimentelle Untersuchungen über das Antikoagulans Marcoumar [3-(l’-Phenyl-propyl)-4 oxy-coumarin] und seinen Antagonisten Konakion (synthetisches Vitamin K₁). Schweiz. med. Wschr. 1953: 471.
• (110) Kaplan E. Congenital and neonatal thrombocytopenic purpura. J. Pediat. 54: 644 1959;
• (111) Keech M. K, Reed R. Electron-microscopy of atheroma. Lancet 2: 1392 1955;
• (112) Kesseler K, Egli H. Untersuchungen über die Gerinnbarkeit des Blutes während und nach körperlicher Arbeit. Int. Z. angew. Physiol. 17: 228 1958;
• (113) Koller F. Über ein peroral wirksames gerinnungshemmendes Pharmakon 3,3’-Methylen-di-[4-oxy-cumarin]. Helv. med. Acta 11: 55 1944;
• (114) Kuschinsky G, Ludewig H. Permeabilitätsänderungen durch Dicumarol, unabhängig von Änderungen der Prothrombinzeit. Arch. exp. Path. Pharmakol. 210: 404 1950;
• (115) Laki K. The clotting of fibrinogen. Blood 8: 845 1953;
• (116) Lasch H. G, Mechelke K, Nusser E. Über Änderungen der Gerinnungs faktoren Prothrombin und VII bei hyper- und hypozirkulatorischen Kreislaufumstellungen der Katze. Dtsch. Arch. klin. Med. 204: 1 1957;
• (117) Lasch H. G, Mechelke K, Nusser E, Sessner H. H. Über Beziehungen zwischen Blutgerinnung und Kreislauffunktion. Z. ges. exp. Med. 129: 484 1958;
• (118) Lasch H. G, Pfisterer I, Schimpf K. Über das Verhalten des Gerinnungsfaktors VII im Kreislauf der Katze. Acta haemat. (Basel) 17: 280 1957;
• (119) Lasch H. G, Roka L. Zur Prothrombinbildung in der Leber. Hoppe-Seylers Z. physiol. Chem. 294: 30 1953;
• (120) Lasch H. G, Roka L. Über den Bildungsmechanismus der Gerinnungsfaktoren Prothrombin und Faktor VII. Klin. Wschr. 1954: 460.
• (121) Ledingham J. C. G. The experimental production of purpura in animals by the introduction of anti-blood-plate sera. Lancet 1: 1673 1914;
• (122) Ledingham J. C. G, Bedson S. P. Experimental purpura. Lancet 1: 311 1915;
• (123) Leeksma C. H. W, Cohen J. A. Determination of the life span of human blood platelets using labelled diisopropyl-fluorophosphonate. J. clin. Invest. 35: 964 1956;
• (124) Lepp E, Chubaty W, Jaques L. B. Effect of phenylindanedione and dicumarol in experimental frostbite. Canad. J. med. Sci. 31: 173 1953;
• (125) Levene C. L. The electron-microscopy of atheroma. Lancet 2: 1216 1955;
• (126) Levene C. L. Electron-microscopy of atheroma. Lancet 1: 105 1956;
• (127) Lewis J. H. Metabolism of fibrinogen I¹³¹ in the dog. VIII. int. Congr. Hernat.. Tokyo: 1960: 241 in program.
• (128) Linke A. Vergleichende Untersuchungen über die Wirkung von Dicumarol und Tromexan auf den Prothrombingehalt des Blutes, die Kapillarresistenz und die Kapillarpermeabilität. Dtsch. med. Wschr. 1952: 775.
• (129) Loeliger E. A, Cleton F. J, Booij H. L, Esch B. v. d. On the metabolism of factor VII. VII. europ. Congr. Haemat.. London: 1959: 223 in program.
• (130) Loeliger A, Hers J. F. P. Chronic antithrombinaemia (antithrombin V) with haemorrhagic diathesis in a case of rheumatoid arthritis with hypergammaglobulinaemia. Thromb. Diath. haem. 1: 499 1957;
• (131) Liischer E. F. Die physiologische Bedeutung der Thrombozyten. Schweiz. med. Wschr. 1956: 345.
• (132) Macfarlane R. G. Critical review: the mechanism of haemostasis. Quart. J. Med. 10: 1 1941;
• (133) Mackay W. The blood-platelet: its clinical significance. Quart. J. Med. 24: 285 1931;
• (134) Madden R. E, Gould R. The turnover rate of fibrinogen in the dog. J. biol. Chem. 196: 641 1952;
• (135) Matis P. Verhütung dicumarolbedingter Gefäßschädigung durch Rutin, unter besonderer Berücksichtigung der Thromboembolieprophylaxe. Dtsch. med. Wschr. 1949: 1576.
• (136) Matis P. Nebenwirkungen gerinnungshemmender Maßnahmen. Proc. I. int. Conf. Thrombosis and Embolism, Basel 1954. Schwabe; Basel: 1955: 853.
• (137) McCarter J. C, Bingham J. B, Meyer O. O. Studies on the hemorrhagic agent 3,31-methylenebis (4-hydroxycoumarin). Amer. J. Path. 20: 651 1944;
• (138) Miescher P, Vorlaender K. O. Immunpathologie in Klinik und Forschung. Thieme; Stuttgart: 1957: 568
• (139) Morris I. G. The effects of anti-leucocyte-platelet serum on young mice. J. Path. Bact. 81: 209 1961;
• (140) Müllertz S. Mechanism of activation and effect of plasmin in blood. Acta physiol. scand. 38 (Suppl. 130) 66 1956;
• (141) Müllertz S. Activation of plasminogen. Ann. N. Y. Acad. Sci. 68: 38 1957;
• (142) Munro H. N, Lazarus S, Bell G. H. The value of capillary strength tests in the diagnosis of vitamin C and vitamin P deficiency in man. Nutr. Abstr. Rev. 17: 291 1947; 1948
• (143) Murphy E. A, Mustard J. F. Dicumarol therapy and platelet turnover. Circ. Res. 9: 402 1961;
• (144) Mustard J. F, Murphy E. A. Platelet survival studies in controls and atherosclerotic subjects with and without anticoagulant therapy. VIII int. Congr. Hernat.. Tokyo: 1960: 217 in program.
• (145) Mustard J. F, Rowsell H. C, Robinson G. A, Hoeksema T. D, Downie H. G. Canine haemophilia B (Christmas disease). Brit. J. Haemat. 6: 259 1960;
• (146) Naimi S, Goldstein R, Proger S. Arteriovenous differences in coagulation and fibrinolysis in normal subjects and in patients with atherosclerosis: a preliminary report. Bull. Tufts-N. E. med. Center 6: 8 1960;
• (147) Nelson Jr T. E, Castronova E, Hyman C. The effect of dicumarol on the transvascular exchange of T-1824-labeled protein in rabbits. Circ. Res. 4: 308 1956;
• (148) Neumayr A, Schmid J. Kapillarpermeabilität und Antithrombin. Schweiz. med. Wschr. 1948: 616.
• (149) Niewiarowski S, Kowalski E, Stachurska J. Influence of fibrinogen derived antithrombin (antithrombin VI) on the blood coagulation system. Acta biochim. polonica 6: 43 1959;
• (150) Nilsson I. M, Blombäck M, Blombäck B. The use of human anti-haemophilic globulin (fraction I—O) in haemophilia A and in von Willebrand’s disease. Acta haemat. (Basel) 24: 116 1960;
• (151) Nolf P. Contribution a l’étude de la coagulation du sang (5e mémoire). La fibrinolyse. Arch. int. Physiol. 6: 306 1908;
• (152) Overman R. S, Stahmann M. A, Sullivan W. R, Huebner C. F, Campbell H. A, Link K. P. Studies on the hemorrhagic sweet clover disease. VII. The effect of 3,31-methylene-bis (4-hydroxycoumarin) on the prothrombin time of the plasma of various animals. J. biol. Chem. 142: 941 1942;
• (153) Owren P. A. Parahaemophilia. Lancet 1: 446 1947;
• (154) Owren P. A. The coagulation of blood. Thesis Acta med. scand. (Suppl. 194) 128: 327 1947;
• (155) Owren P. A. The mechanism of haemostasis. VIII. int. Congr. Hernat.. Tokyo: 1960: 200 in program.
• (156) Pechet L, Alexander B, Tishkoff G. H. Separation, interaction and properties of clotting components essential for prothrombin activation with special reference to Stuart factor. Thromb. Diath. haem. Suppl. 4: 47 1960;
• (157) Peyman M. A. The significance of haemorrhage during the treatment of patients with the coumarin anticogulants. Acta med. scand. (Suppl. 339) 162: 62 1958;
• (158) Pool J. G, Robinson J. In vitro synthesis of coagulation factors by rat liver slices. Amer. J. Physiol. 196: 423 1959;
• (159) Preston F. W, O’Connor W. R, Thompson C. E, Christensen E. N. Clinical use of the anticoagulant phenylindanedione. Circulation 6: 515 1952;
• (160) Prichard R. W, Vann R. L. Congenital afibrinogenemia. Report on a child without fibrinogen and review of the literature. Amer. J. Dis. Child. 88: 703 1954;
• (161) Quick A. J, Hussey C. V, Harris J, Peters K. Occult intravascular clotting by means of intravenous injection of thrombin. Amer. J. Physiol. 197: 791 1959;
• (162) Raccuglia G, Neel J. V. Congenital vascular defect associated with platelet abnormality and antihemophilic factor deficiency. Blood 15: 807 1960;
• (163) Rapaport S. I, Chapman C. G. Coexistent hypercoagulability and acute hypofibrinogenemia in a patient with prostatic carcinoma. Amer. J. Med. 27: 144 1959;
• (164) Ratnoff O. D, Donaldson V. H. Physiologic and pathologic effects of increased fibrinolytic activity in man. Amer. J. Cardiol. 6: 378 1960;
• (165) Reich T, Sternberger L. A. Postoperative thrombin production. Surg. Gynec. Obstet. 102: 463 1956;
• (166) Richards R. K, Cortell R. Studies on the anticoagulant 3,31-methylene-bis-(4-hydroxy coumarin). Proc. Soc. exp. Biol. (N. Y.) 50: 237 1942;
• (167) Rigdon R. H, Wilson H. Capillary permeability and inflammation in rabbits given heparin. Arch. Surg. 43: 64 1941;
• (168) Robertson H. R, Moore J. R, Mersereau W. A. Observations on thrombosis and endothelial repair following application of external pressure to a vein. Canad. J. Surg. 3: 5 1959;
• (169) Robson H. N. Idiopathic thrombocytopenic purpura. Quart. J. Med. 42: 279 1949;
• (170) Robson H. N, Duthie J. J. R. Capillary resistance and adrenocortical activity. Brit. med. J. 2: 971 1950;
• (171) Roderick L. M. A problem in the coagulation of the blood. “Sweet clover disease of cattle”. Amer. J. Physiol. 96: 413 1931;
• (172) Roos J. Blood coagulation as a continuous process. Thromb. Diath. haem. 1: 471 1957;
• (173) Roos J. Purpura hypocoagulabilica. Thesis. 81 Utrecht: 1957
• (174) Roos J, van Arkel C, Keuter E. J. W, Ballieux R. E. Blood coagulation as a continuous process. II. The turnover rate of proconvertin. Acta med. scand. 168: 477 1960;
• (175) Rosenthal M. C. The therapy of disorders of coagulation. J. chron. Dis. 6: 383 1957;
• (176) Roskam J. Contribution a l’étude de la physiologie normale et pathologique du globulin. Arch. int. Physiol. 20: 241 1922; 1923
• (177) Roskam J. Purpuras hémorrhagique et thrombopénie. (Étude expérimentale). Pathogénie du syndrome hémogénique engendrée par l’administration de sérum antiplaquettes. Sang 8: 129 1934;
• (178) Roskam J. Arrest of bleeding. 71 Thomas; Springfield: 1954
• (179) Russek H. E, Zohman B. L. Anticoagulant therapy in acute myocardial infarction. Amer. J. med. Sci. 225: 8 1953;
• (180) Samuels P. B, Webster D. R. The role of venous endothelium in the inception of thrombosis. Ann. Surg. 136: 422 1952;
• (181) Sartori C. Verminderung des Blutungsrisikos durch individuell variierte Dosierung der Antikoagulantien und Therapievorschlage bei Blutungszwischenfallen. Proc. I. int. Conf. Thrombosis and Embolism in Basel 1954. 841 Schwabe; Basel: 1955
• (182) Sawyer W. D, Fletcher A. P, Alkjaersig N, Sherry S. Studies on the thrombolytic activity of human plasma. J. clin. Invest. 39: 426 1960;
• (183) Scharfman W. B, Hosley H. F, Hawkins T, Propp S. Idiopathic thrombocytopenic purpura. An evaluation of the patterns of response to various therapies. J. Amer. med. Ass. 172: 1875 1960;
• (184) Schmidt H, Marx R. Zur Frage der Kapillarschadigung unter Dicumarol-therapie und deren Beeinflussung durch Rutin. Med. Klin. 1951: 812.
• (185) Schofield F. W. Damaged sweet clover: the cause of a new disease in cattle simulating hemorrhagic septicemia and blackleg. J. Amer. vet. med. Ass. 64: 553 1924;
• (186) Sherry S, Fletcher A. P, Alkjaersig N. Fibrinolysis and fibrinolytic activity in man. Physiol. Rev. 39: 343 1959;
• (187) Sherry S, Lindemeyer R. I, Fletcher A. P, Alkjaersig N. Studies on enhanced fibrinolytic activity in man. J. clin. Invest. 38: 810 1959;
• (188) Soulier J. P. Un novel adsorbant des facteurs de coagulation: la bentonite. Rev. Hernat. 14: 26 1959;
• (189) Soulier J. P. Discussion. Thromb. Diath. haem. Suppl. 4: 102 1960;
• (190) Spaet T. H. Vascular factors in the pathogenesis of hemorrhagic syndromes. Blood 7: 641 1952;
• (191) Spaet T. H. Microscopic studies on blood vessels of rats with experimental purpura. Amer. J. Physiol. 170: 333 1952;
• (192) Spaet T. H. Discussion to paper by R. Hasselback, and P. F. Hjort VIII. int. Congr. Hernat.. Tokyo: 1960
• (193) Spaet T. H, Horowitz H. I, Zucker-Franklin D, Cintron J, Biezenski J. J. Reticuloendothelial clearance of blood thromboplastin by rats. Blood 17: 196 1961;
• (194) Stapp W. F. A one stage method for the assay of antihemophilic factor B (AHF B). Scand. J. clin. Lab. Invest. 10: 169 1958;
• (195) Stefanini M. Fibrinolysis and “fibrinolytic purpura”. Blood 7: 1044 1952;
• (196) Stefanini M. Mechanism of blood coagulation in normal and pathologic conditions. Amer. J. Med. 14: 64 1953;
• (197) Stefanini M, Dameshek W. The hemorrhagic disorders. 368 Grune & Stratton; New York: 1955
• (198) Stefanini M, Santiago E. P, Chatterjea J. B, Dameshek W, Salomon L. Corticotropin (ACTH) and cortisone in idiopathic thrombocytopenic purpura. J. Amer. med. Ass. 149: 647 1952;
• (199) Sternberger L. A. Haemostasis with an easily prepared stable thrombin solution. J. clin. Path. 1: 229 1948;
• (200) Sternberger L. A. Preliminary clinical evaluation of thrombin recovery test. J. Amer. med. Ass. 150: 1591 1952;
• (201) Sternberger L. A, Maltaner F. The recovery of preformed thrombin from circulating plasma. Science 114: 414 1951;
• (202) Streuli F. On the purification and conversion of human prothrombin. Thromb. Diath. haem. 3: 194 1959;
• (203) Szabo G, Magyar S, Kertai P, Zádory E. Effect of total body irra-dation on capillary permeability. Nature 182: 885 1958;
• (204) Thies H. A. Die Methoden der Kapillarresistenz- und Kapillarfragilitatsprufung (unter Berucksichtigung der Antikoagulantien). 158 in: Bartelheimer H, Kuchineister H. Kapillaren und Interstitium. Thieme; Stuttgart: 1955
• (205) Tocantins L. M, Stewart H. L. Pathological anatomy of experimental thrombopenie purpura in the dog. Amer. J. Path. 15: 1 1939;
• (206) Tveten H. T. Hemartrose ved hypoproconvertinemi. Nord. Med. 59: 565 1958;
• (207) Volwiler W, Goldsworthy P. D, MacMartin M. P, Wood P. A, Mackay I. R, Fremont-Smith K. Biosynthetic determination with radioactive sulfur of turnover rates of various plasma proteins in normal and cirrhotic man. J. clin. Invest. 34: 1126 1955;
• (208) Voss D, Waaler B. A. Congenital hypoproconvertinemia. A report of 12 cases with total deficiency and 19 cases with partial deficiency. Thromb. Diath. haem. 3: 375 1959;
• (209) Waaler B. A. A simple one-stage method for the assay of antihemophilic A factor with a comment of the plasma level of this factor in hemophilia A. Scand. J. clin. Lab. Invest. 11: 194 1959;
• (210) Wessler S, Reiner L, Freeman D. G, Reimer S. M, Lertzman M. Serum-induced thrombosis. Circulation 20: 864 1959;
• (211) Wilbrandt W, Lüscher E, Asper H. Der Einfluß von Thrombozytenprotein auf die Permeabilität der Blutkapillaren. Helv. physiol. Acta 14: C 81 1956;
• (212) Wintrobe M. M. Clinical hematology. 4th edit.. 1185 Lea & Febiger; Philadelphia: 1956
• (213) Wish L, Furth J, Sheppard C. W, Storey R. H. Disappearance rate of tagged substances from the circulation of roentgen irradiated animals. Amer. J. Roentgenol. 67: 628 1952;
• (214) Witte S. Eine neue Methode zur Untersuchung der Kapillarpermeabilität. Z. ges. exp. Med. 129: 181 1957;
• (215) Witte S. Fluorescenzmikroskopische Untersuchungen über die Kapillarpermeabilität. Z. ges. exp. Med. 129: 358 1957;
• (216) Witte S. Über Beziehungen zwischen Blutgerinnung und Kapillarpermeabilität. Folia haemat. (N. F.) 1: 320 1957;
• (217) Witte S. Die Steigerung der Kapillarpermeabilität durch Blutgerinnungsstörungen. Thromb. Diath. haem. 2: 146 1958;
• (218) Witte S. Über eine intravasale Funktion der Blutgerinnung. Medizinische 1958: 1095.
• (219) Witte S. Morphologische Befunde über die funktionellen Beziehungen zwischen Blutgerinnung und Blutgefäßen. 37 C. H. Boehringer Sohn; Ingelheim: 1960
• (220) Witte S. Physiologie und Pathologie des Thrombins. Folia haemat. (N. F.) 6: 94 1961;
• (221) Witte S, Schricker K. T. Die Bedeutung der Blutgerinnung für die Kapillarpermeabilität. Verh. dtsch. Ges. inn. Med. 63: 634 1957;
• (222) Witte S, Schricker K. T. Mikroskopische Untersuchungen über die Wirkung des Antikoagulans Marcumar auf die Gefäßpermeabilität. Folia haemat. (N. F.) 2: 366 1958;
• (223) Woods M. C, Gamble F. N, Furth J, Bigelow R. R. Control of the postirradiation hemorrhagic state by platelet transfusions. Blood 8: 545 1953;
• (224) Woolf N, Crawford T. Fatty streaks in the aortic intima studied by an immuno-histochemical technique. J. Path. Bact. 80: 405 1960;
• (225) Wright I. S, Prandoni A. The dicoumarin 3,31-methylene-bis-(4-Jiydroxy-coumarin). Its pharmacologic and therapeutic action in man. J. Amer. med. Ass. 120: 1015 1942;
• (226) Wright L. T, Rothman M. Deaths from dicumarol. Arch. Surg. 62: 23 1951;
• (227) Zucker H. D. Clinical experiences with dicumarol. J. Amer. med. Ass. 124: 217 1944;
• (228) Zweifach B. W. Structural makeup of capillary wall. Ann. N. Y. Acad. Sci. 61: 670 1955;
• (229) Yelin G. Prophylactic therapy of hemophilia. J. Newark Beth Israel Hosp. 9: 42 1958;